Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY3372689 in Early Symptomatic Alzheimer's Disease
jRCT2031210449Active, not recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Dec 2021
- Modality
- Small Molecules
01
Overview
Randomised, double-blind trial of ceperognastat in Alzheimer's disease (AD) (3 arms), sponsored by Eli Lilly and Company. Primary endpoint: Change from Baseline to End Time Point in Integrated Alzheimer's Disease Rating Scale (iADRS). Started Dec 2021; status: active, not recruiting.
02
Drugs
ceperognastat
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on jRCT2031210449.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210449.